Elicio Therapeutics, Inc (ELTX)

Over the past six months, Elicio Therapeutics' stock price has fluctuated, showing an 81.39% increase over the past year and a 19.12% increase in the last six months. Key events include reporting Q3 2025 financial results with a narrowed net loss, presenting Phase 2 AMPLIFY-7P data at the Society for Immunotherapy of Cancer's Annual Meeting, stock rallies amid optimism about its immunotherapy pipeline, announcement of ELI-002 7P inducing mKRAS-specific T cell responses in 99% of evaluable patients, a positive recommendation from the IDMC to continue the ELI-002 7P randomized Phase 2 study, and a $10.0 million registered direct offering with institutional investors.

As a clinical-stage biotechnology company, Elicio Therapeutics does not have commercialized products subject to traditional consumer demand seasonality. The demand for its work is driven by the needs for cancer immunotherapies, the progression of its pipeline, and the timelines of its clinical trials. The company's revenue for the last quarter was $0.00, which is typical for a company at this stage of development.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, utilizing its proprietary Amphiphile (AMP) platform to target the lymph nodes. Its major product candidates include ELI-002, a Phase II clinical trial vaccine targeting mKRAS-positive cancers; ELI-007 and ELI-008, preclinical vaccines for mutant B-RAF and mutated tumor protein p53 cancers, respectively; and ELI-004, an AMP-modified CpG adjuvant integral to ELI-002.

Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States, with primary operations focused on research and development, and clinical trials.

Elicio Therapeutics' brand reputation has been positively influenced by progress and promising data from its clinical trials, including robust T cell responses in the Phase 2 AMPLIFY-7P trial, the IDMC's recommendation to continue the AMPLIFY-7P study, and regular corporate updates. No significant negative events explicitly impacting the company's brand reputation were identified.

The ownership structure of Elicio Therapeutics is a mix of retail, institutional, and individual investors, with retail investors holding the largest stake at 52% and insiders owning 33%. Major institutional owners include Knoll Capital Management, LLC, Vanguard Group Inc., Balyasny Asset Management L.P., Geode Capital Management, Llc, Susquehanna International Group, Llp, and Northern Trust Corp. Yekaterina Chudnovsky is the largest individual shareholder.